Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire•09/11/2026•16:02 ET
0
Key Highlights
- ➤Varegacestat PDUFA target action date set for April 28, 2027
- ➤EMA validated Immunome’s varegacestat marketing authorization application
- ➤IM-1021 showed 53% objective response rate across 19 B-NHL patients
- ➤IM-1340 received IND clearance; Phase 1 trial expected by year-end 2026
- ➤Cash, equivalents and marketable securities totaled $461.6 million; runway into 2028
Expert Statements
Clay B. Siegall, President and Chief Executive Officer of Immunome
“We made significant progress across our oncology pipeline in recent months”
Clay B. Siegall, President and Chief Executive Officer of Immunome
“We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA.”
Clay B. Siegall, President and Chief Executive Officer of Immunome
“Beyond varegacestat, we now have three programs in the clinic, with IM-1340 expected to become the fourth by year-end.”
Clay B. Siegall, President and Chief Executive Officer of Immunome
“We are progressing the Phase 1 study of IM-1021, our ROR1-targeted ADC, and look forward to presenting updated Phase 1 data at ASH in December.”
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
* Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)
Get started
Create a free account to read the full story.